glp-1 lawsuit news today Fmr. FDA Commissioner weighs in on Medicare's involvement in prices Ozempic® Lawsuit | July 2026

In late 2024, tirzepatide (Zepbound) became the first GLP-1 and first medication to be approved for sleep apnea

"In combination with diet and exercise, Wegovy is the only obesity medicine proven to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight

In those same high-adoption areas, FSR wallet share rose from 7.68% to 9.05%, suggesting GLP-1 users are trading convenience dining for more experiential occasions. The 35-54 cohort is the key commercial segment here: unlike older users who are broadly cutting back, this group is eating out more (38% report increased frequency), spending more per occasion, and trading up in quality

However, the evidence is still evolving related to how these medications may impact complications related to obesity such as heart disease and diabetes. The Pharmaceutical Strategies Group (PSG), a pharmaceutical management consulting company, surveyed 180 benefits executives representing health plans, employers and unions and found that these drugs are a major concern

Nutrients, 15 (22), 4809

Avoid these medications if: You or a family member has a history of medullary thyroid cancer (MTC) or MEN2 syndrome Youve had a serious allergic reaction to GLP-1 medications in the past You are pregnant or planning pregnancy You are currently on another GLP-1 medication or insulin You have severe gastrointestinal issues , pancreatitis, or advanced kidney/liver problems Youre experiencing significant mental health changes (depression or suicidal thoughts) You are breastfeeding , as it's unknown if the medication passes through breast milk What About Cost & Insurance